Applied DNA Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
Applied DNA Sciences (APDN) Misses Q1 EPS by 34c
February 11, 2021 4:33 PM ESTApplied DNA Sciences (NASDAQ: APDN) reported Q1 EPS of ($0.88), $0.34 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.36 million.
The first quarter marked a very strong start to the fiscal year, reflecting burgeoning demand for our COVID-19 diagnostics and surveillance testing offerings (cumulatively our COVID-19 testing business). Our revenue performance was driven primarily by new client acquisitions for safeCircle, our pooled surveillance testing service, the full benefit of which we believe will be evident in our March 31, 2021 quarter. We also began to deliver quantities... More



